USE OF MODIFIED NOVIRHABDOVIRUSES TO OBTAIN VACCINES

摘要

Use, as a pharmaceutical, of a recombinant novirhabdovirus (NRV) in which the gene (I) encoding the NV protein is inactivated. Independent claims are also included for the following: (1) recombinant NRV in which (I) is inactivated and contains in its genome at least one heterologous gene (II) that encodes a vaccinating antigen (Ag) of an organism pathogenic for fish; (2) cDNA (III) from the genome of the new recombinant NRV; (3) recombinant vector containing (III); and (4) vaccine containing an NRV in which (I) is inactivated. - ACTIVITY : Virucide. - MECHANISM OF ACTION : Vaccine. The recombinant virus G-IHN-SHV is a recombinant infectious hematopoietic necrosis virus (NHIV) in which the NV gene has been replaced by the glycoprotein G gene of hemorrhagic septicemia virus (SHV). It was administered to young trout by adding to the water at 10 4>-5X10 4> plaque-forming units/ml, with exposure for 3 hours. One month later, the fish were challenged with wild-type NHIV and SHV, at the same level of infection. Mortality over the following 28 days was only 1.3%.